摘要
The dependency of prostate cancer (PCa) growth on androgen receptor (AR) signaling has been harnessed to develop first-line therapies for high-risk localized and metastatic PCa treatment. However, the occurrence of aberrant expression, mutated or splice variants of AR confers resistance to androgen ablation therapy (ADT), radiotherapy or chemotherapy in AR-positive PCa. Therapeutic strategies that effectively inhibit the expression and/or transcriptional activity of full-length AR, mutated AR and AR splice variants have remained elusive. In this study, we report that mithramycin (MTM), an antineoplastic antibiotic, suppresses cell proliferation and exhibits dual inhibitory effects on expression and transcriptional activity of AR and AR splice variants. MTM blocks AR recruitment to its genomic targets by occupying AR enhancers and causes downregulation of AR target genes, which includes key DNA repair factors in DNA damage repair (DDR). We show that MTM significantly impairs DDR and enhances the effectiveness of ionizing radiation or the radiomimetic agent Bleomycin in PCa. Thus, the combination of MTM treatment with RT or radiomimetic agents, such as bleomycin, may present a novel effective therapeutic strategy for patients with high-risk, clinically localized PCa.
学科与关键词
- Supraphysiological androgens suppress prostate cancer growth through androgen receptor-mediated DNA damage.Chatterjee Payel; Schweizer Michael T; Lucas Jared M; Coleman Ilsa; Nyquist Michael D; Frank Sander B; Tharakan Robin; Mostaghel Elahe; Luo Jun; Pritchard Colin C; Lam Hung Ming; Corey Eva; Antonarakis Emmanuel S; Denmeade Samuel R; Nelson Peter SJournal of Clinical Investigation, 2019, 130.
- Tautomycin and enzalutamide combination yields synergistic effects on castration-resistant prostate cancerLuo, Mayao; Zhang, Yifan; Xu, Zhuofan; Wu, Chenwei; Ye, Yuedian; Liu, Rui*; Lv, Shidong*; Wei, Qiang*Cell Death Discovery, 2022, 8(1): 471.被引 1
- Integrated analysis reveals FOXA1 and Ku70/Ku80 as targets of ivermectin in prostate cancerLv, Shidong; Wu, Zeyu; Luo, Mayao; Zhang, Yifan; Zhang, Jianqiang; Pascal, Laura E.; Wang, Zhou*; Wei, Qiang*Cell Death & Disease, 2022, 13(9): 754.被引 6
